Search Videos and More
Video
2022 GU ASCO Prostate Cancer Highlights
Prostate Cancer Highlights featuring Jacob Berchuck, MD and Chris Sweeney, MBBS
Video
2022 GU ASCO Bladder Cancer Highlights
Bladder Cancer Highlights featuring Guru Sonpavde, MD
Video
2022 GU ASCO Kidney Cancer Highlights
Kidney Cancer Highlights featuring Vincent Xu, MD and Toni Choueiri, MD
Symposium
2022 ASCO GU Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU Symposium.
News
Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.
Video
Rare Cancer: A Father's Journey with Medullary Kidney Cancer
A father and Air Force recruiter details his journey at Dana-Farber Cancer Institute with medullary kidney cancer - a rare cancer disproportionately affecting African Americans.
News
Targeted Drug Shows Activity Against Brain Metastases in Kidney Cancer
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
Video
Kidney Cancer Research at ESMO
Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
Video
Bladder Cancer Research at ESMO
Dana-Farber's Guru Sonpavde, MD, provides insight on circulating tumor DNA trial in bladder cancer highlighted at ESMO 2021.
News
Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer
T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led by Dana-Farber researchers is addressing both of these issues in patients who have undergone surgery for kidney cancer but have a high risk of recurrence.
News
Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
News
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.